Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PGNY 
Progyny Inc (PGNY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PGNY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -38.99% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.97B USD | Price to earnings Ratio 40.51 | 1Y Target Price 26.75 |
Price to earnings Ratio 40.51 | 1Y Target Price 26.75 | ||
Volume (30-day avg) 1940581 | Beta 1.42 | 52 Weeks Range 13.39 - 36.51 | Updated Date 04/1/2025 |
52 Weeks Range 13.39 - 36.51 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4.66% | Operating Margin (TTM) 5.29% |
Management Effectiveness
Return on Assets (TTM) 6.18% | Return on Equity (TTM) 11.14% |
Valuation
Trailing PE 40.51 | Forward PE 14.51 | Enterprise Value 1700304875 | Price to Sales(TTM) 1.69 |
Enterprise Value 1700304875 | Price to Sales(TTM) 1.69 | ||
Enterprise Value to Revenue 1.46 | Enterprise Value to EBITDA 24.07 | Shares Outstanding 85413296 | Shares Floating 71976919 |
Shares Outstanding 85413296 | Shares Floating 71976919 | ||
Percent Insiders 7.5 | Percent Institutions 106.49 |
Analyst Ratings
Rating 3.6 | Target Price 18.86 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold 7 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Progyny Inc
Company Overview
History and Background
Progyny, Inc. was founded in 2008. It is a benefits management company specializing in fertility and family building benefits solutions.
Core Business Areas
- Fertility Benefits Management: Progyny provides comprehensive fertility benefits management solutions to employers, covering services such as in vitro fertilization (IVF), egg freezing, and other assisted reproductive technologies (ART). They also offer pharmacy benefits.
- Family Building Benefits: Beyond fertility, Progyny offers solutions encompassing adoption and surrogacy benefits.
Leadership and Structure
Pete Anevski is the CEO. The company has a typical corporate structure with departments for sales, marketing, operations, finance, and technology.
Top Products and Market Share
Key Offerings
- Competitors: WINFertility, Carrot Fertility, Kindbody, insurance companies.
- Number of users: Over 5 million lives covered as of December 31, 2023
- Progyny Fertility Benefit: This core offering provides access to fertility treatments, personalized support, and pharmacy benefits through a network of fertility specialists. Progyny claims to have a superior success rate. Exact market share figures are not readily available but Progyny is a market leader. Competitors include WINFertility, Carrot Fertility, and large insurance companies that offer fertility coverage plans, and Kindbody.
- Revenue generated: The fertility benefit drives the majority of Progyny's revenue.
- Competitors: CVS Caremark, Express Scripts, specialty pharmacies.
- Number of users: Included with Progyny Fertility Benefit
- Progyny Rx: This pharmacy benefits offering provides access to fertility medications. While market share data isn't explicitly published, it's a significant portion of Progyny's business. Competitors include traditional pharmacy benefit managers (PBMs) like CVS Caremark and Express Scripts and specialty pharmacies.
- Revenue generated: Significant portion of Progyny's revenue
Market Dynamics
Industry Overview
The fertility benefits market is experiencing significant growth, driven by increasing awareness of infertility, rising demand for family-building benefits, and employer efforts to attract and retain talent. Technological advancements in fertility treatments also contribute to market expansion.
Positioning
Progyny is positioned as a premium fertility benefits provider, emphasizing high success rates, personalized support, and a comprehensive network of specialists. They are a market leader focusing on larger self-insured employers.
Total Addressable Market (TAM)
The TAM for fertility benefits is estimated to be in the billions of dollars and growing. Progyny is positioned to capture a significant share of this market by offering a comprehensive and high-quality solution that appeals to employers seeking to improve employee satisfaction and reduce healthcare costs.
Upturn SWOT Analysis
Strengths
- High clinical success rates
- Strong network of fertility specialists
- Comprehensive benefits offering
- Established relationships with large employers
- Technology-enabled platform
Weaknesses
- Higher cost compared to traditional insurance coverage
- Reliance on employer-sponsored benefits
- Limited brand awareness among individuals
- Vulnerable to economic downturns affecting employer budgets
- Customer concentration risk (reliance on a few large clients)
Opportunities
- Expanding into smaller employer markets
- Offering direct-to-consumer services
- Partnering with insurance companies
- Geographic expansion
- Developing new fertility solutions and technologies
Threats
- Increased competition from other fertility benefits providers
- Changes in insurance regulations
- Economic downturn affecting employer budgets
- Technological disruptions in fertility treatments
- Consolidation in the healthcare industry
Competitors and Market Share
Key Competitors
- WINFertility
- CRTO
- FERT
Competitive Landscape
Progyny's advantages include its focus on high-quality care, comprehensive benefits offering, and technology-enabled platform. Disadvantages include higher costs.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Progyny has experienced strong historical growth, driven by increasing adoption of its fertility benefits solutions among employers.
Future Projections: Analysts project continued revenue growth for Progyny, driven by increasing demand for fertility benefits and the company's expansion into new markets and service offerings.
Recent Initiatives: Recent initiatives include expanding its network of fertility specialists, launching new fertility solutions, and targeting smaller employer markets.
Summary
Progyny is a strong player in the fertility benefits management market, demonstrating substantial growth and profitability. Its comprehensive offering, high success rates, and strong relationships with large employers are key strengths. Progyny needs to be vigilant about competition, economic downturns, and customer concentration risks while continuing to innovate and expand its market reach.
Similar Companies
- CRTO
- FERT
- UNH
- CVS
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is based on available estimates and may not be precise. All investments carry risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Progyny Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2019-10-25 | CEO & Director Mr. Peter Anevski CPA | ||
Sector Healthcare | Industry Healthcare Plans | Full time employees 675 | Website https://www.progyny.com |
Full time employees 675 | Website https://www.progyny.com | ||
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. The company offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. It also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services. In addition, the company offers assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.